RxDoctor Payments Data

Anthony Elias, MD

Medical Oncology · Aurora, CONPI 1679663355

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,685 of the $15,419 with a category attached, or 82.3%. It is spread thinly across 12 manufacturers, the largest accounting for just 23.7%.

$15,419in general payments, 2019–2025

Across 30 payments — averaging $513.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Radius Health, Inc.$4K
  • Eli Lilly$3K
  • Daiichi Sankyo Inc.$3K
  • Stemline Therapeutics Inc.$3K
  • AstraZeneca$1K
  • Gilead$865
  • plus $476 from 6 others
$1,199,894in research payments, 2019–2025

Across 123 payments — averaging $9755.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$341K
  • PTC Therapeutics, Inc.$250K
  • Merck$178K
  • Jazz Pharmaceuticals Inc.$165K
  • Regeneron$149K
  • Epizyme, Inc.$96K
  • plus $21K from 3 others

What the payments were for

  • Consulting fees$12,68582%
  • Speaking & faculty fees$6154%
  • Grants$3502%
  • Travel & lodging$1,1417%
  • Food & beverage$5764%
  • Education$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,419 in reported general payments places this provider in the 80th percentile of 96 medical oncology providers in Colorado.

See all medical oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$34,085
Medicare patients
161
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib12$192,757
VerzenioAbemaciclib11$169,528
Sunitinib Malate14$70,361
Imatinib Mesylate31$46,765
Anastrozole130$3,467
Letrozole53$1,532
Oxycodone Hcl25$581
Tamoxifen Citrate13$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$25$192,75712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 96 medical oncology providers in Colorado.

Other medical oncology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →